Investigating a specific RNA's role in a type of lymphoma linked to AIDS
Role of a latent OriLyt RNA in KSHV latency in primary effusion lymphoma
['FUNDING_R21'] · UNIV OF ARKANSAS FOR MED SCIS · NIH-10896992
This study is looking at how a specific RNA helps certain cancer cells survive, which could lead to new treatments for people with primary effusion lymphoma linked to a virus.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIV OF ARKANSAS FOR MED SCIS (nih funded) |
| Locations | 1 site (LITTLE ROCK, UNITED STATES) |
| Trial ID | NIH-10896992 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding how a particular RNA, known as OriLyt, contributes to the survival of primary effusion lymphoma (PEL) cells, which are associated with Kaposi's sarcoma-associated herpesvirus (KSHV). The study employs advanced techniques like RNA-targeting CRISPR/CasRx to identify viral factors essential for the growth of these cancer cells. By analyzing the expression of latency genes and their role in maintaining the cancer cells, the research aims to uncover critical insights that could lead to new treatment strategies for patients affected by this malignancy.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with primary effusion lymphoma or those who are KSHV-positive and experiencing related health issues.
Not a fit: Patients with other types of lymphomas or those not infected with KSHV may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic approaches for treating primary effusion lymphoma, potentially improving outcomes for patients.
How similar studies have performed: Other research has shown promise in targeting viral factors in cancer treatment, suggesting that this approach could yield significant insights.
Where this research is happening
LITTLE ROCK, UNITED STATES
- UNIV OF ARKANSAS FOR MED SCIS — LITTLE ROCK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MANZANO, MARK — UNIV OF ARKANSAS FOR MED SCIS
- Study coordinator: MANZANO, MARK
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome, Acquired Immunodeficiency Syndrome